Vaginal Estradiol Cost in Oregon (2026): Insurance, Medicaid, and Savings Options

What Does Vaginal Estradiol Actually Cost in Oregon?

The price you pay depends on whether you fill a brand-name product, a generic, or a compounded formulation. Oregon's average retail cash price for vaginal estradiol in 2026 hovers around $120 per month, according to pharmacy pricing aggregator data. That number reflects generic vaginal estradiol cream and tablets at chain pharmacies like Walgreens, Rite Aid, and Fred Meyer locations statewide.

Brand-name products sit higher. Estrace vaginal cream carries a manufacturer list price of approximately $280 per month, while the Vagifem (estradiol vaginal tablet) and Imvexxy (estradiol vaginal insert) brands each list between $250 and $350 depending on dose strength [1]. Few patients pay list price out of pocket. GoodRx and similar platforms show Oregon cash prices for generic vaginal estradiol cream ranging from $35 to $90 at most pharmacies, with the lowest prices concentrated at Costco and independent pharmacies in the Portland metro area.

A 2016 Cochrane systematic review of 30 trials (N = 6,235) found all low-dose vaginal estradiol formulations (cream, tablet, and ring) equally effective for treating genitourinary syndrome of menopause (GSM), meaning cost and preference, not efficacy, should guide product selection [2]. That finding matters for Oregon patients comparing price tags across formulations.

Oregon Medicaid (OHP) Coverage for Vaginal Estradiol

Oregon's Medicaid program, the Oregon Health Plan, covers vaginal estradiol. Prior authorization is required. The PA process typically takes 24 to 72 hours and requires documentation that the patient has a clinical diagnosis of GSM or vulvovaginal atrophy (VVA).

The Oregon Health Authority's Practitioner-Managed Prescription Drug Plan (PMPDP) preferred drug list includes generic estradiol vaginal cream and estradiol vaginal tablets [3]. Brand-name formulations like Imvexxy may require a non-preferred PA demonstrating failure of or intolerance to a preferred product first. Oregon Medicaid pays the pharmacy directly, so qualifying patients have zero or near-zero copays.

To meet PA criteria, prescribers generally must document at least one of the following: vaginal dryness causing functional impairment, dyspareunia, recurrent urinary tract infections linked to vaginal atrophy, or urinary urgency/frequency attributed to GSM. The 2022 Menopause Society position statement notes that "low-dose vaginal estrogen therapy is the most effective treatment for GSM symptoms and should be offered to symptomatic women" [4]. Oregon's PA criteria align with this guidance.

For patients denied on initial PA submission, the OHP appeals process allows a peer-to-peer review. Approval rates after peer-to-peer are high when the prescriber confirms the clinical indication and prior conservative measures (lubricants, moisturizers) proved insufficient.

Compounded Vaginal Estradiol in Oregon: Legality and Pricing

Compounded vaginal estradiol is legal in Oregon through licensed 503A pharmacies. These pharmacies operate under state Board of Pharmacy oversight and federal Drug Quality and Security Act (DQSA) provisions [5]. Oregon does not restrict the compounding of estradiol into vaginal creams, suppositories, or capsules when prepared pursuant to a valid patient-specific prescription.

Pricing from Oregon 503A compounding pharmacies typically ranges from $30 to $45 per month for vaginal estradiol cream or suppositories at standard doses (typically 0.5 mg to 1 mg per application, twice weekly). Some compounders in the Portland and Eugene markets advertise prices as low as $25 per month when patients purchase a 90-day supply. That represents a 70% to 80% reduction compared to brand-name retail pricing.

The trade-off: compounded products lack FDA-approved labeling, undergo less standardized quality testing than manufactured generics, and carry no manufacturer warranty on potency. The FDA has issued guidance stating that compounded drugs "are not FDA-approved" and that patients should understand this distinction [5]. Oregon's Board of Pharmacy requires 503A pharmacies to follow USP <795> and USP <797> standards for non-sterile and sterile compounding, respectively, which provides a baseline quality floor.

For patients considering the compounded route, verifying the pharmacy's accreditation through the Pharmacy Compounding Accreditation Board (PCAB) or checking its Oregon Board of Pharmacy license status adds an extra layer of confidence. Ask the compounder whether they perform third-party potency testing on estradiol batches.

Which Oregon Insurance Plans Cover Vaginal Estradiol?

Most commercial insurance plans available through the Oregon Health Insurance Marketplace and employer-sponsored plans cover at least one vaginal estradiol formulation. Coverage varies by carrier and formulary tier.

Providence Health Plan, the largest commercial insurer in Oregon, lists generic estradiol vaginal cream on its preferred formulary (Tier 2), with typical copays of $15 to $35 per fill. Moda Health, another major Oregon carrier, places generic vaginal estradiol tablets on its preferred tier as well. Kaiser Permanente Northwest covers both generic cream and generic tablets without prior authorization for most plan designs, though brand products require step therapy documentation.

PacificSource, Regence BlueCross BlueShield of Oregon, and SAIF Corporation group plans each have their own formulary structures. The general pattern: generic vaginal estradiol cream and tablets sit on Tier 2 (preferred brand/generic), while brand-name products like Imvexxy or Vagifem land on Tier 3 or require a non-preferred PA.

A key detail many patients miss: under the Affordable Care Act, preventive services mandates do not classify vaginal estradiol as a preventive medication, so cost-sharing applies. This differs from contraceptive coverage. Patients should verify their specific plan's formulary and copay tier before assuming coverage terms.

The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin No. 141 states that "low-dose vaginal estrogen preparations are effective and generally safe for the treatment of vulvovaginal atrophy" and recommends them as first-line pharmacotherapy [6]. Insurance medical directors frequently reference this guideline when approving coverage requests.

How to Get the Cheapest Vaginal Estradiol in Oregon

Six strategies can meaningfully reduce your out-of-pocket cost.

Use a generic. Generic estradiol vaginal cream (0.01%) costs $35 to $90 cash at most Oregon pharmacies, compared to $250+ for brand Estrace cream. The active ingredient is identical [1].

Compare pharmacy prices. Oregon pharmacy pricing varies by 40% or more for the same generic product. Costco pharmacies in Tigard, Clackamas, and Salem consistently post among the lowest cash prices statewide. You do not need a Costco membership to use the pharmacy.

Request a 90-day fill. Pharmacies and insurers typically offer per-unit discounts on 90-day prescriptions, reducing the monthly cost by 10% to 20%.

Use manufacturer savings cards. Allergan (now AbbVie) offers a savings card for Estrace that can reduce brand copays to as low as $25 per fill for commercially insured patients. Therapeutics MD offers a similar program for Imvexxy. These cards do not apply to government insurance (Medicaid, Medicare Part D, Tricare) [7].

Consider compounded formulations. As detailed above, 503A compounded vaginal estradiol runs $30 to $45 per month in Oregon.

Apply for patient assistance. AbbVie's patient assistance program covers Estrace for uninsured patients meeting income thresholds (generally <300% of the federal poverty level). Application processing takes two to four weeks.

Telehealth Access to Vaginal Estradiol in Oregon

Oregon law permits telehealth prescribing of vaginal estradiol. No in-person visit is required for an initial prescription, provided the prescribing clinician conducts an adequate clinical evaluation via synchronous audio-video consultation. Oregon's Telehealth Parity Act (ORS 743A.058) requires insurers to cover telehealth visits at parity with in-person visits, meaning your copay for a telehealth consultation should match your in-person specialist copay [8].

HealthRX and similar telehealth platforms operating in Oregon can prescribe vaginal estradiol after a clinical intake and provider evaluation. The prescription can be sent electronically to any Oregon retail or compounding pharmacy.

One practical note: the Estring vaginal ring (which delivers estradiol over 90 days) requires sizing that some clinicians prefer to do in person, though it is not strictly required. Vaginal cream and tablet prescriptions are straightforward to manage via telehealth alone.

The North American Menopause Society (now The Menopause Society) 2022 hormone therapy position statement notes that "telemedicine may be an appropriate modality for prescribing vaginal estrogen therapy, particularly for patients with mobility limitations or those in rural areas" [4]. Oregon's rural counties (Harney, Lake, Malheur, Wheeler) have limited OB/GYN access, making telehealth a practical channel for GSM treatment in those regions.

Vaginal Estradiol Dosage Forms: Cream vs. Tablet vs. Ring

Three FDA-approved formulations deliver estradiol locally to vaginal tissue. The 2016 Cochrane review (30 RCTs, N = 6,235) found no significant difference in efficacy among them for relieving GSM symptoms including vaginal dryness, dyspareunia, and urinary complaints [2].

Estradiol vaginal cream (0.01%). Applied 2 to 4 grams intravaginally daily for two weeks, then 1 gram twice weekly for maintenance. Generic versions are widely available. Cream can be messy, which some patients find inconvenient.

Estradiol vaginal tablet (10 mcg). One tablet inserted intravaginally daily for two weeks, then one tablet twice weekly. Vagifem and its authorized generic (Yuvafem) are the most common products. Tablets are less messy than cream. A 2019 JAMA Internal Medicine study (N = 45,663 women in the Women's Health Initiative Observational Study) found no increased risk of cardiovascular disease, cancer, or fracture with vaginal estrogen use over a median follow-up of 7.2 years [9].

Estradiol vaginal ring (Estring, 2 mg). Inserted once and left in place for 90 days, then replaced. Delivers approximately 7.5 mcg per day. The ring eliminates the need to remember twice-weekly applications. Some women find insertion and removal difficult without guidance.

Systemic estradiol absorption from all three formulations remains minimal at recommended doses. Serum estradiol levels stay within the postmenopausal range (<20 pg/mL) for most women using low-dose vaginal products, which is why the FDA-approved labeling for these products does not require concomitant progestogen even in women with an intact uterus at standard doses [1].

Safety Considerations and Black Box Warning Context

All vaginal estradiol products carry the class-wide estrogen black box warning mandated by the FDA. This warning references risks identified in the Women's Health Initiative (WHI) trials, which studied oral conjugated equine estrogens at systemic doses [10]. The clinical relevance of this warning to low-dose vaginal estradiol is debated.

The 2022 Menopause Society position statement addresses this directly: "The FDA class labeling for low-dose vaginal estrogen products includes the same boxed warning as systemic estrogen products, but the risks described in the boxed warning have not been demonstrated with low-dose vaginal estrogen" [4]. The Endocrine Society's 2019 clinical practice guideline echoes this view, noting that "low-dose vaginal estrogen is not associated with an increased risk of endometrial hyperplasia" at recommended doses [11].

Oregon clinicians frequently counsel patients that the black box warning reflects a regulatory classification issue rather than a demonstrated risk at vaginal doses. The 2019 WHI observational study (N = 45,663) reinforced this, finding no increase in breast cancer, coronary heart disease, stroke, VTE, or fracture among vaginal estrogen users over 7.2 years of follow-up [9].

Patients with a history of hormone-sensitive breast cancer should discuss vaginal estradiol with their oncologist. ACOG and the Menopause Society both acknowledge that vaginal estradiol may be considered in breast cancer survivors with bothersome GSM symptoms after non-hormonal therapies have failed, though this remains an individualized clinical decision [6].